Brand-new Medexi Pharma Service Center at Brussels Airport

posted on 28th June 2021 by Eddie Saunders
Brand-new Medexi Pharma Service Center at Brussels Airport

Brussels Airport continues to invest in its logistics zone Brucargo, where it took delivery of a new building accommodating 4,000m² of warehousing and office space.

The building will become the home base of Medexi, a joint venture by several established companies in the pharmaceutical industry.

As independent Pharma Service Center, Medexi will take care of the packaging, storage, transhipment and delivery of medical products.

With this new Center, the offer and expertise at Brussels Airport is further expanded.

Medexi is a new joint venture of three companies that, each in their own field, have been active in pharmaceuticals logistics.

Hazgo is a logistics services provider specialised in dangerous goods, including dry ice packaging; Ivemar is active in the transportation and storage of goods that require special care or treatment and Medista is a specialised medical supply company that today ensures the local distribution of Covid-19 vaccines.

“The transportation of pharmaceuticals is one of the specialisations of Brussels Airport,” says Arnaud Feist, CEO of Brussels Airport Company.

“In our logistics zone we already had over 30,000 m² of temperature-controlled warehouses aimed at these shipments and today, with the new Pharma Service Center, we’re adding an extra 2,400 m².

“That these three partners are joining forces to put their expertise at the disposal of all parties involved in pharmaceuticals transport is a nice addition to the current offer at Brucargo”.

“Within Medexi, we bring together our long-standing niche market expertise thus strengthening the pharmaceuticals logistics chain and the position of Brussels Airport as the pharma gateway by excellence of Europe,” explains Tom Heymans, co-founder of Medexi.

“As independent Pharma Service Center we can support all partners, from international forwarders to small research labs and big pharmaceutical corporations”.